175 related articles for article (PubMed ID: 37276911)
1. Identification of MDM2 as a prognostic and immunotherapeutic biomarker in a comprehensive pan-cancer analysis: A promising target for breast cancer, bladder cancer and ovarian cancer immunotherapy.
Zheng J; Miao F; Wang Z; Ma Y; Lin Z; Chen Y; Kong X; Wang Y; Zhuang A; Wu T; Li W
Life Sci; 2023 Aug; 327():121832. PubMed ID: 37276911
[TBL] [Abstract][Full Text] [Related]
2. Identification of m6A suppressor EIF4A3 as a novel cancer prognostic and immunotherapy biomarker through bladder cancer clinical data validation and pan-cancer analysis.
Yan H; Zhang L; Li R
Sci Rep; 2023 Sep; 13(1):16457. PubMed ID: 37777564
[TBL] [Abstract][Full Text] [Related]
3. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
4. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of
Liu J; Zhu B; Chen J; Cao Y
Anticancer Res; 2023 Oct; 43(10):4491-4509. PubMed ID: 37772558
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
7. Pan-Cancer Analysis Shows That ALKBH5 Is a Potential Prognostic and Immunotherapeutic Biomarker for Multiple Cancer Types Including Gliomas.
Wei C; Wang B; Peng D; Zhang X; Li Z; Luo L; He Y; Liang H; Du X; Li S; Zhang S; Zhang Z; Han L; Zhang J
Front Immunol; 2022; 13():849592. PubMed ID: 35444654
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.
Meng W; Jiang Z; Zhang X; Cai B; Ma L; Guan Y
Comput Math Methods Med; 2022; 2022():3119721. PubMed ID: 36466552
[TBL] [Abstract][Full Text] [Related]
9. Identification of SLC12A8 as a valuable prognostic biomarker and immunotherapeutic target by comprehensive pan-cancer analysis.
Yu D; Ma H; Li D; Tang H; Li W; Li M
Gene; 2024 Apr; 903():148211. PubMed ID: 38280496
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and Immunological Significance of CXCR2 in Ovarian Cancer: A Promising Target for Survival Outcome and Immunotherapeutic Response Assessment.
Ji H; Ren M; Liu T; Sun Y
Dis Markers; 2021; 2021():5350232. PubMed ID: 34840630
[TBL] [Abstract][Full Text] [Related]
11. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
12. [STIP1 correlates with tumor immune infiltration and prognosis as a potential immunotherapy target: a pan-cancer bioinformatics analysis].
Guan S; Shen Z; Lin M; Deng H; Fang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jul; 43(7):1179-1193. PubMed ID: 37488801
[TBL] [Abstract][Full Text] [Related]
13. Pan-cancer analysis of the prognostic and immunological role of SNX29: a potential target for survival and immunotherapy.
Xu C; Li F; Liu Z; Yan C; Xiao J
BMC Med Genomics; 2023 Feb; 16(1):34. PubMed ID: 36829159
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance, tumor immune landscape and immunotherapy responses of ADAR in pan-cancer and its association with proliferation and metastasis of bladder cancer.
Yu H; Bai K; Cheng Y; Lv J; Song Q; Yang H; Lu Q; Yang X
Aging (Albany NY); 2023 Jul; 15(13):6302-6330. PubMed ID: 37414093
[TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Analysis Identified CD93 as a Valuable Biomarker for Predicting Patient Prognosis and Immunotherapy Response.
Tong W; Wang G; Zhu L; Bai Y; Liu Z; Yang L; Wu H; Cui T; Zhang Y
Front Mol Biosci; 2021; 8():793445. PubMed ID: 35265666
[No Abstract] [Full Text] [Related]
16. A Comprehensive Pan-Cancer Analysis of 33 Human Cancers Reveals the Immunotherapeutic Value of Aryl Hydrocarbon Receptor.
Mo Z; Li P; Cao Z; Zhang S
Front Immunol; 2021; 12():564948. PubMed ID: 34290693
[TBL] [Abstract][Full Text] [Related]
17. A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2.
Wu X; Chen H; You C; Peng Z
Hereditas; 2023 May; 160(1):21. PubMed ID: 37170390
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
19. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
20. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
Zhao Q; Gao S; Chen X; Zhu X
Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
